Asensus Surgical Receives FDA 510(K) Clearance For An Expanded Indication To Treat Adult And Pediatric Urology Patients With Senhance Surgical System
Portfolio Pulse from Benzinga Newsdesk
Asensus Surgical has received FDA 510(K) clearance for an expanded indication to treat adult and pediatric urology patients with its Senhance Surgical System.
July 23, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Asensus Surgical has received FDA 510(K) clearance for an expanded indication to treat adult and pediatric urology patients with its Senhance Surgical System. This regulatory approval could enhance the company's market position and drive revenue growth.
The FDA clearance allows Asensus Surgical to expand the use of its Senhance Surgical System, potentially increasing its market share and revenue. This is a significant regulatory milestone that is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100